薬理ゲノミクス市場 : 2028年までの世界予測

Report Overview

The pharmacogenomics market is projected to reach USD 5.8 billion by 2028 from an estimated USD 3.5 billion in 2023, at a CAGR of 10.6% during the forecast period.

薬理ゲノミクス市場は、2023年の推定35億米ドルから2028年までに58億米ドルに達すると予測されており、予測期間中のCAGRは10.6%です。

The growth of this market can be attributed to the research and development efforts aimed at drug discovery and development, and growing focus on personalized medicines.

“The kits & reagents segment accounted for the largest share by product & service in 2022.”
In 2022, the kits & reagents segment accounted for the largest share of product type in the global pharmacogenomics market. The factors such as growing demand for high quality reagents for genomics studies, increasing focus on development of personalized medicines, and growing number of research projects in the field of genomics are driving the growth of this market.

 ““The Asia Pacific region is growing in the pharmacogenomics market during the forecast period of 2023-2028.”
The Asia Pacific region is expected to grow at the highest growth rate during the forecast period. Various factors including growing adoption of advanced sequencing technologies and booming healthcare sector are propelling the growth of pharmacogenomics market in the region.
Increased funding and investments from pharmaceutical and biotechnology companies aimed at advancing the healthcare sector are expected to propel the growth of the pharmacogenomics market in the Asia Pacific region. According to R&D Magazine, Asia has become the world’s foremost region in research and development (R&D) investment, claiming over 44% of the global R&D share. The region is steadily gaining an additional half-percent share each year, and if this trend persists, it could represent more than half of all R&D investments by 2030. China is actively enhancing its R&D infrastructure and human resources capabilities, maintaining a consistent commitment to spending, ambition, and long-term planning. These factors are expected to contribute for the highest CAGR of the region  between 2023 to 2028.

The primary interviews conducted for this report can be categorized as follows:
• By Respondent: Supply Side- 70% and Demand Side 30%
• By Designation: Managers – 45%, CXO & Directors – 30%, and Executives – 25%
• By Region: North America -30%, Europe -20%, Asia-Pacific -30%, Latin America -15% and Middle East & Africa- 5%

List of Companies Profiled in the Report:
• Illumina, Inc. (US)
• Thermo Fisher Scientific Inc. (US)
• Danaher Corporation (US)
• Laboratory Corporation of America Holdings (US)
• Charles River Laboratories (US)
• Eurofins Scientific (Luxembourg)
• Bio-Rad Laboratories, Inc. (US)
• Agilent Technologies, Inc. (US)
• BD (US)
• QIAGEN (Netherlands)
• F. Hoffmann-La Roche Ltd. (Switzerland)
• Revvity (US), IQVIA Inc. (US)
• Mesa Labs, Inc. (US)
• Medpace (US)
• MGI Tech Co., Ltd. (China)
• Takara Bio Inc. (Japan)
• PacBio (US)
• New England Biolabs (US)
• BGI (China), Novogene Co., Ltd. (China)
• SOPHiA GENETICS (Switzerland), Fios Genomics (UK)
• Personalis, Inc. (US)
• BioAI Health Inc. (US)
• NeoGenomics Laboratories (US)
• Macrogen, Inc. (South Korea).)

Research Coverage:
This research report categorizes the pharmacogenomics market by product & service (kits & reagents ( sequencing kits and reagents, PCR kits and reagents, microarray kits and reagents, and other kits & reagents) and service), technology (sequencing, PCR, microarray, and other technologies), disease area (cancer, cardiovascular, neurological diseases, and other disease areas), application (personalized medicine, clinical research, and drug discovery & preclinical development), and end user (academic & research institutes, pharmaeutical & biotechechnology companies, and contract research organization)
The report provides in-depth information on significant factors influencing the growth of the pharmacogenomics market, including drivers, trends, challenges, and opportunities. A thorough analysis of major industry players has been undertaken to provide insights into their business profiles, products/services, key strategies, collaborations, partnerships, and agreements. Additionally, the report encompasses recent developments such as new product launches, mergers, and acquisitions within the pharmacogenomics market.
Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall pharmacogenomics market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market’s pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.

The report provides insights on the following pointers:
• Analysis of key drivers (growing incidence and prevalence of chronic and genetic diseases and rising investments and funding to support genomic projects), restraints (challenges in data integration and interpretation, and issues related to drug response variability), opportunities (growing usage of genomics in specialized/personalized medicine), and challenges (ethical & regulatory issues, concern related to patient privacy & data accessibility) influencing the growth of the market.
• Product & Service Development/Innovation: Detailed insights on newly launched products/services of the pharmacogenomics market
• Market Development: Comprehensive information about lucrative markets – the report analyses the market across varied regions.
• Market Diversification: Exhaustive information about new products/services, untapped geographies, recent developments, and investments in the pharmacogenomics market
• Competitive Assessment: Illumina, Inc. (US), Thermo Fisher Scientific Inc. (US), Danaher Corporation (US), Laboratory Corporation of America Holdings (US), Charles River Laboratories (US), Eurofins Scientific (Luxembourg), Bio-Rad Laboratories, Inc. (US), Agilent Technologies, Inc. (US), BD (US), QIAGEN (Netherlands), F. Hoffmann-La Roche Ltd. (Switzerland), Revvity (US), IQVIA Inc. (US), Mesa Labs, Inc. (US), Medpace (US), MGI Tech Co., Ltd. (China), Takara Bio Inc. (Japan), PacBio (US), New England Biolabs (US), among others in the market.

Table of Contents

1            INTRODUCTION            47

1.1         STUDY OBJECTIVES      47

1.2         MARKET DEFINITION   47

1.2.1      INCLUSIONS AND EXCLUSIONS OF STUDY         48

1.2.2      MARKET SEGMENTATION         49

FIGURE 1           PHARMACOGENOMICS MARKET SCOPE             49

1.2.3      YEARS CONSIDERED     50

1.3         CURRENCY        50

1.4         STAKEHOLDERS            50

1.5         LIMITATIONS   51

1.6         RECESSION IMPACT      51

2            RESEARCH METHODOLOGY     52

2.1         RESEARCH DATA           52

FIGURE 2           RESEARCH DESIGN       52

2.1.1      SECONDARY DATA       53

2.1.2      PRIMARY DATA 54

FIGURE 3           PHARMACOGENOMICS MARKET: BREAKDOWN OF PRIMARIES              54

2.2         MARKET SIZE ESTIMATION       55

2.2.1      BOTTOM-UP APPROACH           55

FIGURE 4           MARKET SIZE ESTIMATION: SUPPLY-SIDE ANALYSIS (2022)              55

FIGURE 5           MARKET SIZE ESTIMATION: APPROACH 1 (REVENUE SHARE ANALYSIS), 2022             56

FIGURE 6           ILLUSTRATIVE EXAMPLE OF THERMO FISHER SCIENTIFIC INC.: REVENUE SHARE ANALYSIS (2022) 56

2.2.1.1   Insights from primaries      58

FIGURE 7           MARKET VALIDATION FROM PRIMARY EXPERTS           58

2.2.2      TOP-DOWN APPROACH             58

FIGURE 8           MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH       58

2.3         GROWTH FORECAST    60

FIGURE 9           PHARMACOGENOMICS MARKET: CAGR PROJECTIONS 60

FIGURE 10         PHARMACOGENOMICS MARKET: GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES    61

2.4         MARKET BREAKDOWN AND DATA TRIANGULATION    62

FIGURE 11         DATA TRIANGULATION METHODOLOGY         62

2.5         RESEARCH ASSUMPTIONS         63

2.6         RISK ANALYSIS 63

2.7         RECESSION IMPACT ANALYSIS 63

TABLE 1             GLOBAL INFLATION RATE PROJECTIONS, 2021–2028 (% GROWTH)         63

TABLE 2             US: HEALTH EXPENDITURE, 2019–2022 (USD MILLION) 64

TABLE 3             US: HEALTH EXPENDITURE, 2023–2030 (USD MILLION) 64

3            EXECUTIVE SUMMARY 65

FIGURE 12         PHARMACOGENOMICS MARKET, BY PRODUCT & SERVICE, 2023 VS. 2028 (USD MILLION)     65

FIGURE 13         PHARMACOGENOMICS MARKET, BY TECHNOLOGY, 2023 VS. 2028 (USD MILLION)     66

FIGURE 14         PHARMACOGENOMICS MARKET, BY APPLICATION, 2023 VS. 2028 (USD MILLION)     66

FIGURE 15         PHARMACOGENOMICS MARKET, BY DISEASE AREA, 2023 VS. 2028 (USD MILLION)     67

FIGURE 16         PHARMACOGENOMICS MARKET, BY END USER, 2023 VS. 2028 (USD MILLION) 68

FIGURE 17         GEOGRAPHICAL SNAPSHOT OF PHARMACOGENOMICS MARKET            69

4            PREMIUM INSIGHTS      70

4.1         PHARMACOGENOMICS MARKET OVERVIEW     70

FIGURE 18         RISING INCIDENCE OF CANCER TO SUPPORT MARKET GROWTH          70

4.2         NORTH AMERICA: PHARMACOGENOMICS MARKET, BY PRODUCT & SERVICE AND COUNTRY (2022) 71

FIGURE 19         KITS & REAGENTS SEGMENT ACCOUNTED FOR LARGEST SHARE OF NORTH AMERICAN PHARMACOGENOMICS MARKET IN 2022 71

4.3         PHARMACOGENOMICS MARKET SHARE, BY TECHNOLOGY, 2022              71

FIGURE 20         SEQUENCING SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN 2022  71

4.4         PHARMACOGENOMICS MARKET SHARE, BY APPLICATION, 2022              72

FIGURE 21         PERSONALIZED MEDICINE SEGMENT DOMINATED MARKET IN 2022 72

4.5         PHARMACOGENOMICS MARKET SHARE, BY DISEASE AREA, 2022              72

FIGURE 22         CANCER SEGMENT ACCOUNTED FOR LARGEST SHARE OF PHARMACOGENOMICS MARKET IN 2022            72

4.6         PHARMACOGENOMICS MARKET SHARE, BY END USER, 2022      73

FIGURE 23         ACADEMIC & RESEARCH INSTITUTES SEGMENT DOMINATED MARKET IN 2022             73

4.7         PHARMACOGENOMICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES           73

FIGURE 24         ASIA PACIFIC COUNTRIES TO REGISTER HIGHER GROWTH DURING FORECAST PERIOD     73

5            MARKET OVERVIEW     74

5.1         INTRODUCTION            74

5.2         MARKET DYNAMICS     74

FIGURE 25         PHARMACOGENOMICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES    74

TABLE 4             PHARMACOGENOMICS MARKET: IMPACT ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES    75

5.2.1      DRIVERS            76

5.2.1.1   Growing incidence and prevalence of chronic and genetic diseases          76

FIGURE 26         NUMBER OF PEOPLE 65 OR OLDER WITH ALZHEIMER’S DEMENTIA, 2023            76

5.2.1.2   Rising investments and funding to support genomics projects    77

5.2.1.3   Rising incidence of cancer  78

TABLE 5             CANCER INCIDENCE, 2020 VS. 2040         79

TABLE 6             CANCER PGX-RELATED PHARMACOGENES, DRUG PATHWAYS, AND CANCER DRUGS WITH SIDE EFFECTS        80

5.2.1.4   Increasing collaborations and partnerships between key players and research institutes              80

TABLE 7             COLLABORATIONS AND PARTNERSHIPS BETWEEN KEY PLAYERS AND RESEARCH INSTITUTES 81

5.2.1.5   Increasing focus on translational approach to optimize drug development processes             83

5.2.2      RESTRAINTS     84

5.2.2.1   Challenges in data integration and interpretation         84

5.2.2.2   Issues related to drug response variabilities    84

5.2.3      OPPORTUNITIES           84

5.2.3.1   Use of genomics in specialized/personalized medicine 84

5.2.3.2   AI in pharmacogenomics   85

5.2.3.3   Increasing cost-effectiveness of pharmacogenomics testing        86

5.2.4      CHALLENGES   87

5.2.4.1   Ethical and regulatory hurdles         87

5.2.4.2   Growing concerns related to patient privacy and data access      87

5.3         TECHNOLOGY ANALYSIS           88

5.3.1      SEQUENCING   88

TABLE 8             COMPARISON OF SANGER SEQUENCING AND NGS        88

5.3.2      PCR       89

TABLE 9             COMPARISON OF PCR TECHNOLOGIES 89

5.3.3      MICROARRAY   89

5.4         VALUE CHAIN ANALYSIS            90

FIGURE 27         PHARMACOGENOMICS MARKET: VALUE CHAIN ANALYSIS              92

5.5         SUPPLY CHAIN ANALYSIS          92

FIGURE 28         PHARMACOGENOMICS MARKET: SUPPLY CHAIN ANALYSIS              93

5.6         REGULATORY LANDSCAPE       94

5.6.1      REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS          94

TABLE 10           NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS         94

TABLE 11           EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 94

TABLE 12           ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS         95

TABLE 13           REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS         96

5.6.2      REGULATORY SCENARIO           96

TABLE 14           PHARMACOGENOMICS MARKET: REGULATORY SCENARIO              96

5.7         ECOSYSTEM ANALYSIS 99

5.7.1      PHARMACOGENOMICS PRODUCT VENDORS    99

TABLE 15           PHARMACOGENOMICS PRODUCT VENDORS: ROLE IN ECOSYSTEM     100

5.7.2      PHARMACOGENOMICS SERVICE VENDORS       100

TABLE 16           PHARMACOGENOMICS SERVICE VENDORS: ROLE IN ECOSYSTEM     100

5.7.3      PHARMACOGENOMICS END USERS       101

TABLE 17           PHARMACOGENOMICS END USERS: ROLE IN ECOSYSTEM              101

5.7.4      PHARMACOGENOMICS REGULATORY BODIES 101

TABLE 18           PHARMACOGENOMICS REGULATORY BODIES: ROLE IN ECOSYSTEM     102

5.8         TRENDS/DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS     102

FIGURE 29         REVENUE SHIFT AND NEW REVENUE POCKETS 103

5.9         PRICING ANALYSIS        103

5.9.1      AVERAGE SELLING PRICE OF PHARMACOGENOMICS PRODUCTS, BY KEY PLAYER     104

TABLE 19           AVERAGE SELLING PRICE OF PHARMACOGENOMICS PRODUCTS, BY KEY PLAYER (2022)        104

5.9.2      AVERAGE SELLING PRICE OF PHARMACOGENOMICS PRODUCTS, BY REGION             105

TABLE 20           AVERAGE SELLING PRICE OF PHARMACOGENOMICS PRODUCTS, BY REGION (2022) 105

5.9.3      AVERAGE SELLING PRICE TREND ANALYSIS      105

FIGURE 30         GENOME SEQUENCING PRICING TREND            105

5.10       KEY CONFERENCES AND EVENTS IN 2023–2024 106

TABLE 21           PHARMACOGENOMICS MARKET: LIST OF CONFERENCES AND EVENTS             106

5.11       PORTER’S FIVE FORCES ANALYSIS         107

TABLE 22           PHARMACOGENOMICS MARKET: PORTER’S FIVE FORCES ANALYSIS          107

5.11.1    THREAT OF NEW ENTRANTS    108

5.11.2    THREAT OF SUBSTITUTES         108

5.11.3    BARGAINING POWER OF SUPPLIERS     108

5.11.4    BARGAINING POWER OF BUYERS           108

5.11.5    INTENSITY OF COMPETITIVE RIVALRY 108

5.12       PATENT ANALYSIS        109

FIGURE 31         PATENT APPLICATIONS FOR PHARMACOGENOMICS MARKET, JANUARY 2013–DECEMBER 2023 109

TABLE 23           INDICATIVE LIST OF PATENTS IN PHARMACOGENOMICS MARKET            109

5.13       KEY STAKEHOLDERS AND BUYING CRITERIA    111

5.13.1    KEY STAKEHOLDERS IN BUYING PROCESS         111

FIGURE 32         INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR PHARMACOGENOMICS PRODUCTS AND SERVICES       111

TABLE 24           INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR PHARMACOGENOMICS PRODUCTS AND SERVICES       111

5.13.2    BUYING CRITERIA FOR PHARMACOGENOMICS MARKET            112

FIGURE 33         BUYING CRITERIA FOR PHARMACOGENOMICS PRODUCTS              112

TABLE 25           BUYING CRITERIA FOR PHARMACOGENOMICS PRODUCTS AND SERVICES, BY END USER    113

6            PHARMACOGENOMICS MARKET, BY PRODUCT & SERVICE        114

6.1         INTRODUCTION            115

TABLE 26           PHARMACOGENOMICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)          115

6.2         KITS & REAGENTS         115

TABLE 27           PHARMACOGENOMICS KITS & REAGENTS MARKET, BY TYPE, 2021–2028 (USD MILLION)          116

TABLE 28           PHARMACOGENOMICS KITS & REAGENTS MARKET, BY REGION, 2021–2028 (USD MILLION)       116

TABLE 29           NORTH AMERICA: PHARMACOGENOMICS KITS & REAGENTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)         117

TABLE 30           EUROPE: PHARMACOGENOMICS KITS & REAGENTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)            117

TABLE 31           ASIA PACIFIC: PHARMACOGENOMICS KITS & REAGENTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)         118

TABLE 32           LATIN AMERICA: PHARMACOGENOMICS KITS & REAGENTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)         118

TABLE 33           MIDDLE EAST & AFRICA: PHARMACOGENOMICS KITS & REAGENTS MARKET, BY REGION, 2021–2028 (USD MILLION)      119

TABLE 34           MIDDLE EAST: PHARMACOGENOMICS KITS & REAGENTS MARKET, BY REGION, 2021–2028 (USD MILLION)            119

6.2.1      SEQUENCING KITS & REAGENTS            119

6.2.1.1   Development of new sequencing technologies to drive market   119

TABLE 35           SEQUENCING KITS & REAGENTS MARKET, BY REGION, 2021–2028 (USD MILLION)     120

TABLE 36           NORTH AMERICA: SEQUENCING KITS & REAGENTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)            120

TABLE 37           EUROPE: SEQUENCING KITS & REAGENTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)    121

TABLE 38           ASIA PACIFIC: SEQUENCING KITS & REAGENTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)    121

TABLE 39           LATIN AMERICA: SEQUENCING KITS & REAGENTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)    122

TABLE 40           MIDDLE EAST & AFRICA: SEQUENCING KITS & REAGENTS MARKET, BY REGION, 2021–2028 (USD MILLION)            122

TABLE 41           MIDDLE EAST: SEQUENCING KITS & REAGENTS MARKET, BY REGION, 2021–2028 (USD MILLION)       122

6.2.2      PCR KITS & REAGENTS 123

6.2.2.1   Ensures standardized and reliable identification of genetic variants related to drug metabolism          123

TABLE 42           PCR KITS & REAGENTS MARKET, BY REGION, 2021–2028 (USD MILLION)          123

TABLE 43           NORTH AMERICA: PCR KITS & REAGENTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)    124

TABLE 44           EUROPE: PCR KITS & REAGENTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)     124

TABLE 45           ASIA PACIFIC: PCR KITS & REAGENTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)          125

TABLE 46           LATIN AMERICA: PCR KITS & REAGENTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)    125

TABLE 47           MIDDLE EAST & AFRICA: PCR KITS & REAGENTS MARKET, BY REGION, 2021–2028 (USD MILLION)       126

TABLE 48           MIDDLE EAST: PCR KITS & REAGENTS MARKET, BY REGION, 2021–2028 (USD MILLION)          126

6.2.3      MICROARRAY KITS & REAGENTS            126

6.2.3.1   Cost-effectiveness and high-throughput capabilities to support adoption 126

TABLE 49           MICROARRAY KITS & REAGENTS MARKET, BY REGION, 2021–2028 (USD MILLION)     127

TABLE 50           NORTH AMERICA: MICROARRAY KITS & REAGENTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)            127

TABLE 51           EUROPE: MICROARRAY KITS & REAGENTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)    128

TABLE 52           ASIA PACIFIC: MICROARRAY KITS & REAGENTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)    128

TABLE 53           LATIN AMERICA: MICROARRAY KITS & REAGENTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)    129

TABLE 54           MIDDLE EAST & AFRICA: MICROARRAY KITS & REAGENTS MARKET, BY REGION, 2021–2028 (USD MILLION)            129

TABLE 55           MIDDLE EAST: MICROARRAY KITS & REAGENTS MARKET, BY REGION, 2021–2028 (USD MILLION)       129

6.2.4      OTHER KITS & REAGENTS         130

TABLE 56           OTHER KITS & REAGENTS MARKET, BY REGION, 2021–2028 (USD MILLION) 130

TABLE 57           NORTH AMERICA: OTHER KITS & REAGENTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)    131

TABLE 58           EUROPE: OTHER KITS & REAGENTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)          131

TABLE 59           ASIA PACIFIC: OTHER KITS & REAGENTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)    132

TABLE 60           LATIN AMERICA: OTHER KITS & REAGENTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)    132

TABLE 61           MIDDLE EAST & AFRICA: OTHER KITS & REAGENTS MARKET, BY REGION, 2021–2028 (USD MILLION)  133

TABLE 62          MIDDLE EAST: OTHER KITS & REAGENTS MARKET, BY REGION, 2021–2028 (USD MILLION)          133

6.3         SERVICES          133

6.3.1      SCALABILITY OF CRO SERVICES ALLOWS TAILORED SOLUTIONS              133

TABLE 63           PHARMACOGENOMICS SERVICES MARKET, BY REGION, 2021–2028 (USD MILLION)     134

TABLE 64           NORTH AMERICA: PHARMACOGENOMICS SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)            134

TABLE 65           EUROPE: PHARMACOGENOMICS SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)    135

TABLE 66           ASIA PACIFIC: PHARMACOGENOMICS SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)    135

TABLE 67           LATIN AMERICA: PHARMACOGENOMICS SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)            136

TABLE 68           MIDDLE EAST & AFRICA: PHARMACOGENOMICS SERVICES MARKET, BY REGION, 2021–2028 (USD MILLION)            136

TABLE 69           MIDDLE EAST: PHARMACOGENOMICS SERVICES MARKET, BY REGION, 2021–2028 (USD MILLION)       136

7            PHARMACOGENOMICS MARKET, BY TECHNOLOGY      137

7.1         INTRODUCTION            138

TABLE 70           PHARMACOGENOMICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 138

7.2         SEQUENCING   138

7.2.1      GROWING ADOPTION OF GENETIC TESTING FOR DIAGNOSIS AND TREATMENT TO DRIVE MARKET           138

TABLE 71           SEQUENCING MARKET, BY REGION, 2021–2028 (USD MILLION)              139

TABLE 72           NORTH AMERICA: SEQUENCING MARKET, BY COUNTRY, 2021–2028 (USD MILLION)     139

TABLE 73           EUROPE: SEQUENCING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 140

TABLE 74           ASIA PACIFIC: SEQUENCING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 140

TABLE 75           LATIN AMERICA: SEQUENCING MARKET, BY COUNTRY, 2021–2028 (USD MILLION)     141

TABLE 76           MIDDLE EAST & AFRICA: SEQUENCING MARKET, BY REGION, 2021–2028 (USD MILLION)          141

TABLE 77           MIDDLE EAST: SEQUENCING MARKET, BY REGION, 2021–2028 (USD MILLION) 141

7.3         PCR       142

7.3.1      INCREASED USE OF PCR FOR DRUG AND BIOMARKER DISCOVERY TO PROPEL MARKET          142

TABLE 78           PCR MARKET, BY REGION, 2021–2028 (USD MILLION)    143

TABLE 79           NORTH AMERICA: PCR MARKET, BY COUNTRY, 2021–2028 (USD MILLION)          143

TABLE 80           EUROPE: PCR MARKET, BY COUNTRY, 2021–2028 (USD MILLION)          144

TABLE 81           ASIA PACIFIC: PCR MARKET, BY COUNTRY, 2021–2028 (USD MILLION)          144

TABLE 82           LATIN AMERICA: PCR MARKET, BY COUNTRY, 2021–2028 (USD MILLION)          145

TABLE 83           MIDDLE EAST & AFRICA: PCR MARKET, BY REGION, 2021–2028 (USD MILLION) 145

TABLE 84           MIDDLE EAST: PCR MARKET, BY REGION, 2021–2028 (USD MILLION)          145

7.4         MICROARRAY   146

7.4.1      MICROARRAY HELPS UNDERSTAND GENETIC BASIS OF DRUG METABOLISM   146

TABLE 85           MICROARRAY MARKET, BY REGION, 2021–2028 (USD MILLION)              146

TABLE 86           NORTH AMERICA: MICROARRAY MARKET, BY COUNTRY, 2021–2028 (USD MILLION)     147

TABLE 87           EUROPE: MICROARRAY MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 147

TABLE 88           ASIA PACIFIC: MICROARRAY MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 148

TABLE 89           LATIN AMERICA: MICROARRAY MARKET, BY COUNTRY, 2021–2028 (USD MILLION)     148

TABLE 90           MIDDLE EAST & AFRICA: MICROARRAY MARKET, BY REGION, 2021–2028 (USD MILLION)          149

TABLE 91           MIDDLE EAST: MICROARRAY MARKET, BY REGION, 2021–2028 (USD MILLION) 149

7.5         OTHER TECHNOLOGIES            149

TABLE 92           OTHER TECHNOLOGIES MARKET, BY REGION, 2021–2028 (USD MILLION)          150

TABLE 93           NORTH AMERICA: OTHER TECHNOLOGIES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)    150

TABLE 94           EUROPE: OTHER TECHNOLOGIES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)          151

TABLE 95          ASIA PACIFIC: OTHER TECHNOLOGIES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)          151

TABLE 96           LATIN AMERICA: OTHER TECHNOLOGIES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)    152

TABLE 97           MIDDLE EAST & AFRICA: OTHER TECHNOLOGIES MARKET, BY REGION, 2021–2028 (USD MILLION)       152

TABLE 98           MIDDLE EAST: OTHER TECHNOLOGIES MARKET, BY REGION, 2021–2028 (USD MILLION)          152

8            PHARMACOGENOMICS MARKET, BY APPLICATION       153

8.1         INTRODUCTION            154

TABLE 99           PHARMACOGENOMICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 154

8.2         PERSONALIZED MEDICINE        154

8.2.1      INCREASING PREVALENCE OF CHRONIC DISEASES TO DRIVE MARKET              154

TABLE 100         PHARMACOGENOMICS MARKET FOR PERSONALIZED MEDICINE, BY REGION, 2021–2028 (USD MILLION)         155

TABLE 101         NORTH AMERICA: PHARMACOGENOMICS MARKET FOR PERSONALIZED MEDICINE, BY COUNTRY, 2021–2028 (USD MILLION)    156

TABLE 102         EUROPE: PHARMACOGENOMICS MARKET FOR PERSONALIZED MEDICINE, BY COUNTRY, 2021–2028 (USD MILLION)    156

TABLE 103         ASIA PACIFIC: PHARMACOGENOMICS MARKET FOR PERSONALIZED MEDICINE, BY COUNTRY, 2021–2028 (USD MILLION)    157

TABLE 104         LATIN AMERICA: PHARMACOGENOMICS MARKET FOR PERSONALIZED MEDICINE, BY COUNTRY, 2021–2028 (USD MILLION)    157

TABLE 105         MIDDLE EAST & AFRICA: PHARMACOGENOMICS MARKET FOR PERSONALIZED MEDICINE, BY REGION, 2021–2028 (USD MILLION)        158

TABLE 106         MIDDLE EAST: PHARMACOGENOMICS MARKET FOR PERSONALIZED MEDICINE, BY REGION, 2021–2028 (USD MILLION)        158

8.3         CLINICAL RESEARCH    158

8.3.1      GROWING NUMBER OF CLINICAL TRIALS FOR PHARMACOGENOMICS TO DRIVE MARKET       158

TABLE 107         PHARMACOGENOMICS MARKET FOR CLINICAL RESEARCH, BY REGION, 2021–2028 (USD MILLION)       159

TABLE 108         NORTH AMERICA: PHARMACOGENOMICS MARKET FOR CLINICAL RESEARCH, BY COUNTRY, 2021–2028 (USD MILLION) 160

TABLE 109         EUROPE: PHARMACOGENOMICS MARKET FOR CLINICAL RESEARCH, BY COUNTRY, 2021–2028 (USD MILLION)     160

TABLE 110         ASIA PACIFIC: PHARMACOGENOMICS MARKET FOR CLINICAL RESEARCH, BY COUNTRY, 2021–2028 (USD MILLION)     161

TABLE 111         LATIN AMERICA: PHARMACOGENOMICS MARKET FOR CLINICAL RESEARCH, BY COUNTRY, 2021–2028 (USD MILLION) 161

TABLE 112         MIDDLE EAST & AFRICA: PHARMACOGENOMICS MARKET FOR CLINICAL RESEARCH, BY REGION, 2021–2028 (USD MILLION)     162

TABLE 113         MIDDLE EAST: PHARMACOGENOMICS MARKET FOR CLINICAL RESEARCH, BY REGION, 2021–2028 (USD MILLION)         162

8.4         DRUG DISCOVERY & PRECLINICAL DEVELOPMENT      162

8.4.1      INCREASING APPLICATIONS OF PHARMACOGENOMICS IN DRUG DISCOVERY AND DEVELOPMENT TO SUPPORT MARKET GROWTH       162

TABLE 114         PHARMACOGENOMICS MARKET FOR DRUG DISCOVERY & PRECLINICAL DEVELOPMENT, BY REGION, 2021–2028 (USD MILLION)  163

TABLE 115         NORTH AMERICA: PHARMACOGENOMICS MARKET FOR DRUG DISCOVERY & PRECLINICAL DEVELOPMENT, BY COUNTRY, 2021–2028 (USD MILLION)          163

TABLE 116         EUROPE: PHARMACOGENOMICS MARKET FOR DRUG DISCOVERY & PRECLINICAL DEVELOPMENT, BY COUNTRY, 2021–2028 (USD MILLION)          164

TABLE 117         ASIA PACIFIC: PHARMACOGENOMICS MARKET FOR DRUG DISCOVERY & PRECLINICAL DEVELOPMENT, BY COUNTRY, 2021–2028 (USD MILLION)          164

TABLE 118         LATIN AMERICA: PHARMACOGENOMICS MARKET FOR DRUG DISCOVERY & PRECLINICAL DEVELOPMENT, BY COUNTRY, 2021–2028 (USD MILLION)          165

TABLE 119         MIDDLE EAST & AFRICA: PHARMACOGENOMICS MARKET FOR DRUG DISCOVERY & PRECLINICAL DEVELOPMENT, BY REGION, 2021–2028 (USD MILLION) 165

TABLE 120         MIDDLE EAST: PHARMACOGENOMICS MARKET FOR DRUG DISCOVERY & PRECLINICAL DEVELOPMENT, BY REGION, 2021–2028 (USD MILLION)          165

9            PHARMACOGENOMICS MARKET, BY DISEASE AREA      166

9.1         INTRODUCTION            167

TABLE 121         PHARMACOGENOMICS MARKET, BY DISEASE AREA, 2021–2028 (USD MILLION) 167

9.2         CANCER             167

9.2.1      INCREASING PREVALENCE OF CANCER TO DRIVE MARKET       167

TABLE 122         PHARMACOGENOMICS MARKET FOR CANCER, BY REGION, 2021–2028 (USD MILLION)          168

TABLE 123         NORTH AMERICA: PHARMACOGENOMICS MARKET FOR CANCER, BY COUNTRY, 2021–2028 (USD MILLION)         168

TABLE 124         EUROPE: PHARMACOGENOMICS MARKET FOR CANCER, BY COUNTRY, 2021–2028 (USD MILLION)    169

TABLE 125         ASIA PACIFIC: PHARMACOGENOMICS MARKET FOR CANCER, BY COUNTRY, 2021–2028 (USD MILLION)            169

TABLE 126         LATIN AMERICA: PHARMACOGENOMICS MARKET FOR CANCER, BY COUNTRY, 2021–2028 (USD MILLION)         170

TABLE 127         MIDDLE EAST & AFRICA: PHARMACOGENOMICS MARKET FOR CANCER, BY REGION, 2021–2028 (USD MILLION)             170

TABLE 128         MIDDLE EAST: PHARMACOGENOMICS MARKET FOR CANCER, BY REGION, 2021–2028 (USD MILLION)  170

9.3         CARDIOVASCULAR DISEASE     171

9.3.1      RISING DEMAND FOR PRECISION MEDICINE TO SUPPORT MARKET GROWTH          171

TABLE 129         PHARMACOGENOMICS MARKET FOR CARDIOVASCULAR DISEASE, BY REGION, 2021–2028 (USD MILLION)             171

TABLE 130         NORTH AMERICA: PHARMACOGENOMICS MARKET FOR CARDIOVASCULAR DISEASE, BY COUNTRY, 2021–2028 (USD MILLION)  172

TABLE 131         EUROPE: PHARMACOGENOMICS MARKET FOR CARDIOVASCULAR DISEASE, BY COUNTRY, 2021–2028 (USD MILLION)  172

TABLE 132         ASIA PACIFIC: PHARMACOGENOMICS MARKET FOR CARDIOVASCULAR DISEASE, BY COUNTRY, 2021–2028 (USD MILLION)  173

TABLE 133         LATIN AMERICA: PHARMACOGENOMICS MARKET FOR CARDIOVASCULAR DISEASE, BY COUNTRY, 2021–2028 (USD MILLION)  173

TABLE 134         MIDDLE EAST & AFRICA: PHARMACOGENOMICS MARKET FOR CARDIOVASCULAR DISEASE, BY REGION, 2021–2028 (USD MILLION)      174

TABLE 135         MIDDLE EAST: PHARMACOGENOMICS MARKET FOR CARDIOVASCULAR DISEASE, BY REGION, 2021–2028 (USD MILLION)      174

9.4         NEUROLOGICAL DISORDERS    174

9.4.1      GROWING DEMAND FOR PERSONALIZED MEDICINE TO SUPPORT MARKET GROWTH        174

TABLE 136         PHARMACOGENOMICS MARKET FOR NEUROLOGICAL DISORDERS, BY REGION, 2021–2028 (USD MILLION)       175

TABLE 137         NORTH AMERICA: PHARMACOGENOMICS MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2021–2028 (USD MILLION) 175

TABLE 138         EUROPE: PHARMACOGENOMICS MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2021–2028 (USD MILLION) 176

TABLE 139         ASIA PACIFIC: PHARMACOGENOMICS MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2021–2028 (USD MILLION) 176

TABLE 140         LATIN AMERICA: PHARMACOGENOMICS MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2021–2028 (USD MILLION) 177

TABLE 141         MIDDLE EAST & AFRICA: PHARMACOGENOMICS MARKET FOR NEUROLOGICAL DISORDERS, BY REGION, 2021–2028 (USD MILLION)    177

TABLE 142         MIDDLE EAST: PHARMACOGENOMICS MARKET FOR NEUROLOGICAL DISORDERS, BY REGION, 2021–2028 (USD MILLION)    177

9.5         OTHER DISEASE AREAS 178

TABLE 143         PHARMACOGENOMICS MARKET FOR OTHER DISEASE AREAS, BY REGION, 2021–2028 (USD MILLION)  178

TABLE 144         NORTH AMERICA: PHARMACOGENOMICS MARKET FOR OTHER DISEASE AREAS, BY COUNTRY, 2021–2028 (USD MILLION)           179

TABLE 145         EUROPE: PHARMACOGENOMICS MARKET FOR OTHER DISEASE AREAS, BY COUNTRY, 2021–2028 (USD MILLION)           179

TABLE 146         ASIA PACIFIC: PHARMACOGENOMICS MARKET FOR OTHER DISEASE AREAS, BY COUNTRY, 2021–2028 (USD MILLION)           180

TABLE 147         LATIN AMERICA: PHARMACOGENOMICS MARKET FOR OTHER DISEASE AREAS, BY COUNTRY, 2021–2028 (USD MILLION)           180

TABLE 148         MIDDLE EAST & AFRICA: PHARMACOGENOMICS MARKET FOR OTHER DISEASE AREAS, BY REGION, 2021–2028 (USD MILLION) 181

TABLE 149         MIDDLE EAST: PHARMACOGENOMICS MARKET FOR OTHER DISEASE AREAS, BY REGION, 2021–2028 (USD MILLION) 181

10          PHARMACOGENOMICS MARKET, BY END USER 182

10.1       INTRODUCTION            183

TABLE 150         PHARMACOGENOMICS MARKET, BY END USER, 2021–2028 (USD MILLION) 183

10.2       ACADEMIC & RESEARCH INSTITUTES   183

10.2.1    INCREASING RESEARCH ACTIVITIES AND FUNDING TO DRIVE GROWTH          183

TABLE 151         PHARMACOGENOMICS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2021–2028 (USD MILLION)      184

TABLE 152         NORTH AMERICA: PHARMACOGENOMICS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2021–2028 (USD MILLION)              184

TABLE 153         EUROPE: PHARMACOGENOMICS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2021–2028 (USD MILLION)          185

TABLE 154         ASIA PACIFIC: PHARMACOGENOMICS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2021–2028 (USD MILLION)              185

TABLE 155         LATIN AMERICA: PHARMACOGENOMICS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2021–2028 (USD MILLION)              186

TABLE 156         MIDDLE EAST & AFRICA: PHARMACOGENOMICS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2021–2028 (USD MILLION)              186

TABLE 157         MIDDLE EAST: PHARMACOGENOMICS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2021–2028 (USD MILLION)              186

10.3       PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES   187

10.3.1    GROWING STRATEGIC ALLIANCES FOR DRUG DEVELOPMENT AND PERSONALIZED MEDICINE TO PROPEL MARKET           187

TABLE 158         PHARMACOGENOMICS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2021–2028 (USD MILLION) 188

TABLE 159         NORTH AMERICA: PHARMACOGENOMICS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION) 188

TABLE 160         EUROPE: PHARMACOGENOMICS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION) 189

TABLE 161         ASIA PACIFIC: PHARMACOGENOMICS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION) 189

TABLE 162         LATIN AMERICA: PHARMACOGENOMICS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION) 190

TABLE 163         MIDDLE EAST & AFRICA: PHARMACOGENOMICS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2021–2028 (USD MILLION) 190

TABLE 164         MIDDLE EAST: PHARMACOGENOMICS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2021–2028 (USD MILLION) 190

10.4       CONTRACT RESEARCH ORGANIZATIONS          191

10.4.1    INCREASING OUTSOURCING TREND IN GENOMICS FIELD TO PROPEL MARKET            191

TABLE 165         PHARMACOGENOMICS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2021–2028 (USD MILLION)           191

TABLE 166         NORTH AMERICA: PHARMACOGENOMICS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2021–2028 (USD MILLION)          192

TABLE 167         EUROPE: PHARMACOGENOMICS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 192

TABLE 168         ASIA PACIFIC: PHARMACOGENOMICS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2021–2028 (USD MILLION)          193

TABLE 169         LATIN AMERICA: PHARMACOGENOMICS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2021–2028 (USD MILLION)          193

TABLE 170         MIDDLE EAST & AFRICA: PHARMACOGENOMICS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2021–2028 (USD MILLION)          194

TABLE 171         MIDDLE EAST: PHARMACOGENOMICS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2021–2028 (USD MILLION)          194

11          PHARMACOGENOMICS MARKET, BY REGION    195

11.1       INTRODUCTION            196

TABLE 172         PHARMACOGENOMICS MARKET, BY REGION, 2021–2028 (USD MILLION)          196

11.2       NORTH AMERICA          196

FIGURE 34         NORTH AMERICA: PHARMACOGENOMICS MARKET SNAPSHOT        197

TABLE 173         NORTH AMERICA: PHARMACOGENOMICS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)    197

TABLE 174         NORTH AMERICA: PHARMACOGENOMICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)            198

TABLE 175         NORTH AMERICA: PHARMACOGENOMICS KITS & REAGENTS MARKET, BY TYPE, 2021–2028 (USD MILLION)    198

TABLE 176         NORTH AMERICA: PHARMACOGENOMICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)          199

TABLE 177         NORTH AMERICA: PHARMACOGENOMICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)           199

TABLE 178         NORTH AMERICA: PHARMACOGENOMICS MARKET, BY DISEASE AREA, 2021–2028 (USD MILLION)          200

TABLE 179         NORTH AMERICA: PHARMACOGENOMICS MARKET, BY END USER, 2021–2028 (USD MILLION)             200

11.2.1    US         201

11.2.1.1 US dominates North American pharmacogenomics market        201

TABLE 180         US: PHARMACOGENOMICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)          202

TABLE 181         US: PHARMACOGENOMICS KITS & REAGENTS MARKET, BY TYPE, 2021–2028 (USD MILLION)             202

TABLE 182         US: PHARMACOGENOMICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)     202

TABLE 183         US: PHARMACOGENOMICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)     203

TABLE 184         US: PHARMACOGENOMICS MARKET, BY DISEASE AREA, 2021–2028 (USD MILLION)     203

TABLE 185         US: PHARMACOGENOMICS MARKET, BY END USER, 2021–2028 (USD MILLION) 204

11.2.2    CANADA            204

11.2.2.1 Growing research activities in genomics field to drive market     204

TABLE 186         CANADA: PHARMACOGENOMICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)       205

TABLE 187         CANADA: PHARMACOGENOMICS KITS & REAGENTS MARKET, BY TYPE, 2021–2028 (USD MILLION)       205

TABLE 188         CANADA: PHARMACOGENOMICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)          206

TABLE 189         CANADA: PHARMACOGENOMICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)          206

TABLE 190         CANADA: PHARMACOGENOMICS MARKET, BY DISEASE AREA, 2021–2028 (USD MILLION)          207

TABLE 191         CANADA: PHARMACOGENOMICS MARKET, BY END USER, 2021–2028 (USD MILLION)          207

11.2.3    RECESSION IMPACT ON NORTH AMERICAN PHARMACOGENOMICS MARKET            208

11.3       EUROPE             208

TABLE 192         EUROPE: PHARMACOGENOMICS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)          209

TABLE 193         EUROPE: PHARMACOGENOMICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)       209

TABLE 194         EUROPE: PHARMACOGENOMICS KITS & REAGENTS MARKET, BY TYPE, 2021–2028 (USD MILLION)       210

TABLE 195         EUROPE: PHARMACOGENOMICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)          210

TABLE 196         EUROPE: PHARMACOGENOMICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)          211

TABLE 197         EUROPE: PHARMACOGENOMICS MARKET, BY DISEASE AREA, 2021–2028 (USD MILLION)          211

TABLE 198         EUROPE: PHARMACOGENOMICS MARKET, BY END USER, 2021–2028 (USD MILLION)     212

11.3.1    GERMANY         212

11.3.1.1 Growing strategic alliances among industry players and research institutes to support market growth       212

TABLE 199         GERMANY: PHARMACOGENOMICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)       213

TABLE 200        GERMANY: PHARMACOGENOMICS KITS & REAGENTS MARKET, BY TYPE, 2021–2028 (USD MILLION)       213

TABLE 201         GERMANY: PHARMACOGENOMICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)          214

TABLE 202        GERMANY: PHARMACOGENOMICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)          214

TABLE 203        GERMANY: PHARMACOGENOMICS MARKET, BY DISEASE AREA, 2021–2028 (USD MILLION)          215

TABLE 204         GERMANY: PHARMACOGENOMICS MARKET, BY END USER, 2021–2028 (USD MILLION)          215

11.3.2    UK         216

11.3.2.1 Increasing government funding for genomics projects to propel market   216

TABLE 205         UK: PHARMACOGENOMICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)          217

TABLE 206         UK: PHARMACOGENOMICS KITS & REAGENTS MARKET, BY TYPE, 2021–2028 (USD MILLION)             217

TABLE 207         UK: PHARMACOGENOMICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)     218

TABLE 208         UK: PHARMACOGENOMICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)     218

TABLE 209         UK: PHARMACOGENOMICS MARKET, BY DISEASE AREA, 2021–2028 (USD MILLION)     219

TABLE 210         UK: PHARMACOGENOMICS MARKET, BY END USER, 2021–2028 (USD MILLION) 219

11.3.3    FRANCE             219

11.3.3.1 Increasing government initiatives to boost market growth          219

TABLE 211         FRANCE: PHARMACOGENOMICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)       220

TABLE 212         FRANCE: PHARMACOGENOMICS KITS & REAGENTS MARKET, BY TYPE, 2021–2028 (USD MILLION)       220

TABLE 213         FRANCE: PHARMACOGENOMICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)          221

TABLE 214         FRANCE: PHARMACOGENOMICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)          221

TABLE 215         FRANCE: PHARMACOGENOMICS MARKET, BY DISEASE AREA, 2021–2028 (USD MILLION)          222

TABLE 216         FRANCE: PHARMACOGENOMICS MARKET, BY END USER, 2021–2028 (USD MILLION)     222

11.3.4    ITALY   223

11.3.4.1 Favorable funding programs to support market growth 223

TABLE 217         ITALY: PHARMACOGENOMICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)       223

TABLE 218         ITALY: PHARMACOGENOMICS KITS & REAGENTS MARKET, BY TYPE, 2021–2028 (USD MILLION)             224

TABLE 219         ITALY: PHARMACOGENOMICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)          224

TABLE 220         ITALY: PHARMACOGENOMICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)          225

TABLE 221         ITALY: PHARMACOGENOMICS MARKET, BY DISEASE AREA, 2021–2028 (USD MILLION)          225

TABLE 222         ITALY: PHARMACOGENOMICS MARKET, BY END USER, 2021–2028 (USD MILLION)     226

11.3.5    SPAIN   226

11.3.5.1 Government funding for research in pharmacogenomics and precision medicine to drive market    226

TABLE 223         SPAIN: PHARMACOGENOMICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)       227

TABLE 224         SPAIN: PHARMACOGENOMICS KITS & REAGENTS MARKET, BY TYPE, 2021–2028 (USD MILLION)             227

TABLE 225         SPAIN: PHARMACOGENOMICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)          228

TABLE 226         SPAIN: PHARMACOGENOMICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)          228

TABLE 227         SPAIN: PHARMACOGENOMICS MARKET, BY DISEASE AREA, 2021–2028 (USD MILLION)          228

TABLE 228         SPAIN: PHARMACOGENOMICS MARKET, BY END USER, 2021–2028 (USD MILLION)     229

11.3.6    REST OF EUROPE           229

TABLE 229         REST OF EUROPE: PHARMACOGENOMICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)            230

TABLE 230         REST OF EUROPE: PHARMACOGENOMICS KITS & REAGENTS MARKET, BY TYPE, 2021–2028 (USD MILLION)    230

TABLE 231         REST OF EUROPE: PHARMACOGENOMICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)          231

TABLE 232         REST OF EUROPE: PHARMACOGENOMICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)           231

TABLE 233         REST OF EUROPE: PHARMACOGENOMICS MARKET, BY DISEASE AREA, 2021–2028 (USD MILLION)          232

TABLE 234         REST OF EUROPE: PHARMACOGENOMICS MARKET, BY END USER, 2021–2028 (USD MILLION)             232

11.3.7    RECESSION IMPACT ON EUROPEAN PHARMACOGENOMICS MARKET              233

11.4       ASIA PACIFIC    233

FIGURE 35         ASIA PACIFIC: PHARMACOGENOMICS MARKET SNAPSHOT              234

TABLE 235         ASIA PACIFIC: PHARMACOGENOMICS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)          235

TABLE 236         ASIA PACIFIC: PHARMACOGENOMICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)   235

TABLE 237         ASIA PACIFIC: PHARMACOGENOMICS KITS & REAGENTS MARKET, BY TYPE, 2021–2028 (USD MILLION)    236

TABLE 238         ASIA PACIFIC: PHARMACOGENOMICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)          236

TABLE 239         ASIA PACIFIC: PHARMACOGENOMICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)           237

TABLE 240         ASIA PACIFIC: PHARMACOGENOMICS MARKET, BY DISEASE AREA, 2021–2028 (USD MILLION)            237

TABLE 241         ASIA PACIFIC: PHARMACOGENOMICS MARKET, BY END USER, 2021–2028 (USD MILLION)          238

11.4.1    CHINA  238

11.4.1.1 Increasing research and development spending to support market growth              238

TABLE 242         CHINA: PHARMACOGENOMICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)       239

TABLE 243         CHINA: PHARMACOGENOMICS KITS & REAGENTS MARKET, BY TYPE, 2021–2028 (USD MILLION)             239

TABLE 244         CHINA: PHARMACOGENOMICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)          240

TABLE 245         CHINA: PHARMACOGENOMICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)          240

TABLE 246         CHINA: PHARMACOGENOMICS MARKET, BY DISEASE AREA, 2021–2028 (USD MILLION)          241

TABLE 247         CHINA: PHARMACOGENOMICS MARKET, BY END USER, 2021–2028 (USD MILLION)     241

11.4.2    JAPAN  242

11.4.2.1 Growing focus on development of new pharmacogenomic services to drive market              242

TABLE 248         JAPAN: PHARMACOGENOMICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)       243

TABLE 249         JAPAN: PHARMACOGENOMICS KITS & REAGENTS MARKET, BY TYPE, 2021–2028 (USD MILLION)             243

TABLE 250         JAPAN: PHARMACOGENOMICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)          243

TABLE 251         JAPAN: PHARMACOGENOMICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)          244

TABLE 252         JAPAN: PHARMACOGENOMICS MARKET, BY DISEASE AREA, 2021–2028 (USD MILLION)          244

TABLE 253         JAPAN: PHARMACOGENOMICS MARKET, BY END USER, 2021–2028 (USD MILLION)     244

11.4.3    INDIA   245

11.4.3.1 Growing prevalence of chronic diseases to drive market             245

TABLE 254         INDIA: PHARMACOGENOMICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)       246

TABLE 255         INDIA: PHARMACOGENOMICS KITS & REAGENTS MARKET, BY TYPE, 2021–2028 (USD MILLION)             246

TABLE 256         INDIA: PHARMACOGENOMICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)          246

TABLE 257         INDIA: PHARMACOGENOMICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)          247

TABLE 258         INDIA: PHARMACOGENOMICS MARKET, BY DISEASE AREA, 2021–2028 (USD MILLION)          247

TABLE 259         INDIA: PHARMACOGENOMICS MARKET, BY END USER, 2021–2028 (USD MILLION)     248

11.4.4    AUSTRALIA       248

11.4.4.1 Increase in research activities to propel market            248

TABLE 260         AUSTRALIA: PHARMACOGENOMICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)       249

TABLE 261         AUSTRALIA: PHARMACOGENOMICS KITS & REAGENTS MARKET, BY TYPE, 2021–2028 (USD MILLION)    249

TABLE 262         AUSTRALIA: PHARMACOGENOMICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)          250

TABLE 263         AUSTRALIA: PHARMACOGENOMICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)           250

TABLE 264         AUSTRALIA: PHARMACOGENOMICS MARKET, BY DISEASE AREA, 2021–2028 (USD MILLION)            251

TABLE 265         AUSTRALIA: PHARMACOGENOMICS MARKET, BY END USER, 2021–2028 (USD MILLION)          251

11.4.5    SOUTH KOREA 251

11.4.5.1 Increasing investments in genomics research to drive market     251

TABLE 266         SOUTH KOREA: PHARMACOGENOMICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)            252

TABLE 267         SOUTH KOREA: PHARMACOGENOMICS KITS & REAGENTS MARKET, BY TYPE, 2021–2028 (USD MILLION)    252

TABLE 268         SOUTH KOREA: PHARMACOGENOMICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)          253

TABLE 269         SOUTH KOREA: PHARMACOGENOMICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)           253

TABLE 270         SOUTH KOREA: PHARMACOGENOMICS MARKET, BY DISEASE AREA, 2021–2028 (USD MILLION)            254

TABLE 271         SOUTH KOREA: PHARMACOGENOMICS MARKET, BY END USER, 2021–2028 (USD MILLION)             254

11.4.6    REST OF ASIA PACIFIC  254

TABLE 272         REST OF ASIA PACIFIC: PHARMACOGENOMICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)            255

TABLE 273         REST OF ASIA PACIFIC: PHARMACOGENOMICS KITS & REAGENTS MARKET, BY TYPE, 2021–2028 (USD MILLION)           256

TABLE 274         REST OF ASIA PACIFIC: PHARMACOGENOMICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)          256

TABLE 275         REST OF ASIA PACIFIC: PHARMACOGENOMICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)           257

TABLE 276         REST OF ASIA PACIFIC: PHARMACOGENOMICS MARKET, BY DISEASE AREA, 2021–2028 (USD MILLION)          257

TABLE 277         REST OF ASIA PACIFIC: PHARMACOGENOMICS MARKET, BY END USER, 2021–2028 (USD MILLION)    258

11.4.7    RECESSION IMPACT ON ASIA PACIFIC PHARMACOGENOMICS MARKET              258

11.5       LATIN AMERICA             259

TABLE 278         LATIN AMERICA: PHARMACOGENOMICS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)    259

TABLE 279         LATIN AMERICA: PHARMACOGENOMICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)            260

TABLE 280         LATIN AMERICA: PHARMACOGENOMICS KITS & REAGENTS MARKET, BY TYPE, 2021–2028 (USD MILLION)    260

TABLE 281         LATIN AMERICA: PHARMACOGENOMICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)          261

TABLE 282         LATIN AMERICA: PHARMACOGENOMICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)           261

TABLE 283         LATIN AMERICA: PHARMACOGENOMICS MARKET, BY DISEASE AREA, 2021–2028 (USD MILLION)            262

TABLE 284         LATIN AMERICA: PHARMACOGENOMICS MARKET, BY END USER, 2021–2028 (USD MILLION)             262

11.5.1    BRAZIL 262

11.5.1.1 Increasing investments in biopharmaceutical research to propel market   262

TABLE 285         BRAZIL: PHARMACOGENOMICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)       263

TABLE 286         BRAZIL: PHARMACOGENOMICS KITS & REAGENTS MARKET, BY TYPE, 2021–2028 (USD MILLION)       263

TABLE 287         BRAZIL: PHARMACOGENOMICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)          264

TABLE 288         BRAZIL: PHARMACOGENOMICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)          264

TABLE 289         BRAZIL: PHARMACOGENOMICS MARKET, BY DISEASE AREA, 2021–2028 (USD MILLION)          265

TABLE 290         BRAZIL: PHARMACOGENOMICS MARKET, BY END USER, 2021–2028 (USD MILLION)     265

11.5.2    MEXICO             266

11.5.2.1 Increasing genomics research activities to drive market 266

TABLE 291         MEXICO: PHARMACOGENOMICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)       266

TABLE 292         MEXICO: PHARMACOGENOMICS KITS & REAGENTS MARKET, BY TYPE, 2021–2028 (USD MILLION)       267

TABLE 293         MEXICO: PHARMACOGENOMICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)          267

TABLE 294         MEXICO: PHARMACOGENOMICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)          268

TABLE 295         MEXICO: PHARMACOGENOMICS MARKET, BY DISEASE AREA, 2021–2028 (USD MILLION)          268

TABLE 296         MEXICO: PHARMACOGENOMICS MARKET, BY END USER, 2021–2028 (USD MILLION)     269

11.5.3    REST OF LATIN AMERICA          269

TABLE 297         REST OF LATIN AMERICA: PHARMACOGENOMICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)            269

TABLE 298         REST OF LATIN AMERICA: PHARMACOGENOMICS KITS & REAGENTS MARKET, BY TYPE, 2021–2028 (USD MILLION)           270

TABLE 299         REST OF LATIN AMERICA: PHARMACOGENOMICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)          270

TABLE 300         REST OF LATIN AMERICA: PHARMACOGENOMICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)           271

TABLE 301         REST OF LATIN AMERICA: PHARMACOGENOMICS MARKET, BY DISEASE AREA, 2021–2028 (USD MILLION)          271

TABLE 302         REST OF LATIN AMERICA: PHARMACOGENOMICS MARKET, BY END USER, 2021–2028 (USD MILLION)    272

11.5.4    RECESSION IMPACT ON LATIN AMERICAN PHARMACOGENOMICS MARKET            272

11.6       MIDDLE EAST & AFRICA             273

TABLE 303         MIDDLE EAST & AFRICA: PHARMACOGENOMICS MARKET, BY REGION, 2021–2028 (USD MILLION)       273

TABLE 304         MIDDLE EAST & AFRICA: PHARMACOGENOMICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)            273

TABLE 305         MIDDLE EAST & AFRICA: PHARMACOGENOMICS KITS & REAGENTS MARKET, BY TYPE, 2021–2028 (USD MILLION)           274

TABLE 306         MIDDLE EAST & AFRICA: PHARMACOGENOMICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)          274

TABLE 307         MIDDLE EAST & AFRICA: PHARMACOGENOMICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)           275

TABLE 308         MIDDLE EAST & AFRICA: PHARMACOGENOMICS MARKET, BY DISEASE AREA, 2021–2028 (USD MILLION)          275

TABLE 309         MIDDLE EAST & AFRICA: PHARMACOGENOMICS MARKET, BY END USER, 2021–2028 (USD MILLION)    276

11.6.1    MIDDLE EAST  276

TABLE 310         MIDDLE EAST: PHARMACOGENOMICS MARKET, BY REGION, 2021–2028 (USD MILLION)          276

TABLE 311         MIDDLE EAST: PHARMACOGENOMICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)   277

TABLE 312         MIDDLE EAST: PHARMACOGENOMICS KITS & REAGENTS MARKET, BY TYPE, 2021–2028 (USD MILLION)    277

TABLE 313         MIDDLE EAST: PHARMACOGENOMICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)          278

TABLE 314         MIDDLE EAST: PHARMACOGENOMICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)           278

TABLE 315         MIDDLE EAST: PHARMACOGENOMICS MARKET, BY DISEASE AREA, 2021–2028 (USD MILLION)            279

TABLE 316         MIDDLE EAST: PHARMACOGENOMICS MARKET, BY END USER, 2021–2028 (USD MILLION)          279

11.6.1.1 GCC countries     280

11.6.1.1.1            Increasing government initiatives for pharmacogenomics to propel market   280

TABLE 317         GCC COUNTRIES: PHARMACOGENOMICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)            280

TABLE 318         GCC COUNTRIES: PHARMACOGENOMICS KITS & REAGENTS MARKET, BY TYPE, 2021–2028 (USD MILLION)    281

TABLE 319         GCC COUNTRIES: PHARMACOGENOMICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)          281

TABLE 320         GCC COUNTRIES: PHARMACOGENOMICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)           282

TABLE 321         GCC COUNTRIES: PHARMACOGENOMICS MARKET, BY DISEASE AREA, 2021–2028 (USD MILLION)          282

TABLE 322         GCC COUNTRIES: PHARMACOGENOMICS MARKET, BY END USER, 2021–2028 (USD MILLION)             283

11.6.1.2 Rest of Middle East            283

TABLE 323         REST OF MIDDLE EAST: PHARMACOGENOMICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)            283

TABLE 324         REST OF MIDDLE EAST: PHARMACOGENOMICS KITS & REAGENTS MARKET, BY TYPE, 2021–2028 (USD MILLION)           284

TABLE 325         REST OF MIDDLE EAST: PHARMACOGENOMICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)          284

TABLE 326         REST OF MIDDLE EAST: PHARMACOGENOMICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)           285

TABLE 327         REST OF MIDDLE EAST: PHARMACOGENOMICS MARKET, BY DISEASE AREA, 2021–2028 (USD MILLION)          285

TABLE 328         REST OF MIDDLE EAST: PHARMACOGENOMICS MARKET, BY END USER, 2021–2028 (USD MILLION)    286

11.6.2    AFRICA 286

11.6.2.1 Growing prevalence of HIV & cancer to drive market   286

TABLE 329         AFRICA: PHARMACOGENOMICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)       287

TABLE 330         AFRICA: PHARMACOGENOMICS KITS & REAGENTS MARKET, BY TYPE, 2021–2028 (USD MILLION)       287

TABLE 331         AFRICA: PHARMACOGENOMICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)          288

TABLE 332         AFRICA: PHARMACOGENOMICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)          288

TABLE 333         AFRICA: PHARMACOGENOMICS MARKET, BY DISEASE AREA, 2021–2028 (USD MILLION)          288

TABLE 334         AFRICA: PHARMACOGENOMICS MARKET, BY END USER, 2021–2028 (USD MILLION)     289

11.6.3    RECESSION IMPACT ON MIDDLE EAST & AFRICA PHARMACOGENOMICS MARKET            289

12          COMPETITIVE LANDSCAPE       290

12.1       OVERVIEW        290

12.2       STRATEGIES ADOPTED BY KEY PLAYERS           290

FIGURE 36         PHARMACOGENOMICS MARKET: STRATEGIES ADOPTED BY KEY PLAYERS   291

12.3       REVENUE SHARE ANALYSIS       292

FIGURE 37         REVENUE SHARE ANALYSIS OF TOP PLAYERS IN PHARMACOGENOMICS MARKET, 2018–2022 (USD MILLION)      292

12.4       MARKET SHARE ANALYSIS         292

FIGURE 38         PHARMACOGENOMICS MARKET SHARE, BY KEY PLAYER (2022)              293

TABLE 335         PHARMACOGENOMICS MARKET: INTENSITY OF COMPETITIVE RIVALRY             293

12.5       COMPANY EVALUATION MATRIX          295

12.5.1    STARS  295

12.5.2    EMERGING LEADERS    296

12.5.3    PERVASIVE PLAYERS     296

12.5.4    PARTICIPANTS 296

FIGURE 39         PHARMACOGENOMICS MARKET: COMPANY EVALUATION MATRIX (2022) 296

12.5.5    COMPANY FOOTPRINT 297

TABLE 336         PRODUCT & SERVICE FOOTPRINT         298

TABLE 337         REGIONAL FOOTPRINT             299

12.6       STARTUP/SME EVALUATION MATRIX   300

12.6.1    PROGRESSIVE COMPANIES       300

12.6.2    RESPONSIVE COMPANIES          300

12.6.3    DYNAMIC COMPANIES 300

12.6.4    STARTING BLOCKS       300

FIGURE 40         PHARMACOGENOMICS MARKET: STARTUP/SME EVALUATION MATRIX (2022) 301

12.7       COMPETITIVE BENCHMARKING            302

TABLE 338         PHARMACOGENOMICS MARKET: DETAILED LIST OF KEY STARTUPS/SMES           302

TABLE 339         PHARMACOGENOMICS MARKET: PRODUCT & SERVICE AND REGIONAL FOOTPRINT OF KEY STARTUPS/SMES          304

12.8       COMPETITIVE SCENARIO          305

TABLE 340         PHARMACOGENOMICS MARKET: PRODUCT & SERVICE LAUNCHES, JANUARY 2020–DECEMBER 2023      305

TABLE 341         PHARMACOGENOMICS MARKET: DEALS, JANUARY 2020−DECEMBER 2023 306

TABLE 342         PHARMACOGENOMICS MARKET: OTHER DEVELOPMENTS, JANUARY 2020− DECEMBER 2023           307

13          COMPANY PROFILES    308

13.1       KEY PLAYERS   308

(Business Overview, Products/Solutions/Services Offered, Recent Developments, MnM view (Key strengths/Right to win, Strategic choices made, Weakness/competitive threats)*

13.1.1    ILLUMINA, INC. 308

TABLE 343         ILLUMINA, INC.: BUSINESS OVERVIEW  308

FIGURE 41         ILLUMINA, INC.: COMPANY SNAPSHOT (2022)  309

13.1.2    THERMO FISHER SCIENTIFIC INC.          315

TABLE 344         THERMO FISHER SCIENTIFIC INC.: BUSINESS OVERVIEW              315

FIGURE 42         THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2022)   316

13.1.3    F. HOFFMANN-LA ROCHE LTD. 320

TABLE 345         F. HOFFMANN-LA ROCHE LTD.: BUSINESS OVERVIEW  320

FIGURE 43         F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2022)              321

13.1.4    QIAGEN             325

TABLE 346         QIAGEN: BUSINESS OVERVIEW 325

FIGURE 44         QIAGEN: COMPANY SNAPSHOT (2022)  326

13.1.5    DANAHER CORPORATION         333

TABLE 347         DANAHER CORPORATION: BUSINESS OVERVIEW           333

FIGURE 45         DANAHER CORPORATION: COMPANY SNAPSHOT (2022)              334

13.1.6    LABORATORY CORPORATION OF AMERICA HOLDINGS             337

TABLE 348         LABORATORY CORPORATION OF AMERICA HOLDINGS: BUSINESS OVERVIEW    337

FIGURE 46         LABORATORY CORPORATION OF AMERICA HOLDINGS: COMPANY SNAPSHOT (2022)    338

13.1.7    EUROFINS SCIENTIFIC  340

TABLE 349         EUROFINS SCIENTIFIC: BUSINESS OVERVIEW    340

FIGURE 47         EUROFINS SCIENTIFIC: COMPANY SNAPSHOT (2022)    341

13.1.8    CHARLES RIVER LABORATORIES            343

TABLE 350         CHARLES RIVER LABORATORIES: BUSINESS OVERVIEW 343

FIGURE 48         CHARLES RIVER LABORATORIES: COMPANY SNAPSHOT (2022)              344

13.1.9    BIO-RAD LABORATORIES, INC. 346

TABLE 351         BIO-RAD LABORATORIES, INC.: BUSINESS OVERVIEW   346

FIGURE 49         BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2022)              347

13.1.10  AGILENT TECHNOLOGIES, INC.             349

TABLE 352         AGILENT TECHNOLOGIES, INC.: BUSINESS OVERVIEW 349

FIGURE 50         AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2022)              350

13.1.11  BECTON, DICKINSON AND COMPANY  354

TABLE 353         BECTON, DICKINSON AND COMPANY: BUSINESS OVERVIEW              354

FIGURE 51         BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2023)   355

13.1.12  REVVITY            358

TABLE 354         REVVITY: BUSINESS OVERVIEW 358

FIGURE 52         REVVITY: COMPANY SNAPSHOT (2022) 359

13.1.13  IQVIA, INC.        362

TABLE 355         IQVIA, INC.: BUSINESS OVERVIEW          362

FIGURE 53         IQVIA, INC.: COMPANY SNAPSHOT (2022)          363

13.1.14  MESA LABS, INC.            365

TABLE 356         MESA LABORATORIES, INC.: BUSINESS OVERVIEW         365

FIGURE 54         MESA LABS, INC.: COMPANY SNAPSHOT (2022) 366

13.1.15  MEDPACE, INC. 368

TABLE 357         MEDPACE, INC.: BUSINESS OVERVIEW  368

FIGURE 55         MEDPACE, INC.: COMPANY SNAPSHOT (2022)   368

13.1.16  MGI TECH CO., LTD.     370

TABLE 358         MGI TECH CO., LTD.: BUSINESS OVERVIEW       370

FIGURE 56         MGI TECH CO., LTD.: COMPANY SNAPSHOT (2022)        370

13.2       OTHER PLAYERS           374

13.2.1    PACBIO 374

TABLE 359         PACBIO: COMPANY OVERVIEW 374

13.2.2    TAKARA BIO INC.           375

TABLE 360         TAKARA BIO INC.: COMPANY OVERVIEW           375

13.2.3    NEW ENGLAND BIOLABS           377

TABLE 361         NEW ENGLAND BIOLABS: COMPANY OVERVIEW            377

13.2.4    BGI       378

TABLE 362         BGI: COMPANY OVERVIEW        378

13.2.5    NOVOGENE CO., LTD.  379

TABLE 363         NOVOGENE CO., LTD.: COMPANY OVERVIEW   379

13.2.6    SOPHIA GENETICS        380

TABLE 364         SOPHIA GENETICS: COMPANY OVERVIEW         380

13.2.7    FIOS GENOMICS            381

TABLE 365         FIOS GENOMICS: COMPANY OVERVIEW             381

13.2.8    PERSONALIS, INC.          382

TABLE 366         PERSONALIS, INC.: COMPANY OVERVIEW          382

13.2.9    NEOGENOMICS LABORATORIES            383

TABLE 367         NEOGENOMICS LABORATORIES: COMPANY OVERVIEW              383

13.2.10  BIOAI HEALTH INC.       385

TABLE 368         BIOAI HEALTH INC.: COMPANY OVERVIEW       385

13.2.11  MACROGEN, INC.           386

TABLE 369         MACROGEN, INC.: COMPANY OVERVIEW           386

*Details on Business Overview, Products/Solutions/Services Offered, Recent Developments, MnM view (Key strengths/Right to win, Strategic choices made, Weakness/competitive threats)* might not be captured in case of unlisted companies.

14          APPENDIX         387

14.1       DISCUSSION GUIDE      387

14.2       KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL             393

14.3       CUSTOMIZATION OPTIONS      395

14.4       RELATED REPORTS       395

14.5       AUTHOR DETAILS         396